linjc16/ctgov huggingface dataset:
A Neurocognitive Model of Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate thought processes and neural mechanisms that may contribute to the development of habitual behaviors. The investigators hypothesize that patients with AN will perform differently than people without eating disorders on a series of neuropsychological tasks and will show different neural activation patterns in functional neuroimaging scans.

Detailed Description
-----------------
Patients with Anorexia Nervosa (AN) have extreme difficulty changing their eating behavior, even when they express desire for change. These behaviors seem to override all other potential responses, and can appear perseverative, or habitual. The purpose of this study is to investigate thought processes and neural mechanisms that may contribute to the development of habitual behaviors. The investigators hypothesize that patients with AN will perform differently than people without eating disorders on a series of neuropsychological tasks and will show different neural activation patterns in functional neuroimaging scans.

Official Title
-----------------
A Neurocognitive Model of Anorexia Nervosa

Conditions
-----------------
Anorexia Nervosa

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: DSM-IV-TR™ diagnosis of anorexia nervosa (restricting or binge-purge subtype), current or prior; Age 16-45; Inpatient on GCRU Medically stable. Exclusion: Any other current major Axis I disorder (including current bulimia nervosa), except major depression; History of concussion, seizure disorder, or other neurological illness; History of learning disability; Acute Suicidality Healthy comparison group: Inclusion: No current or past psychiatric illness; Age 16-45 No history of binge eating or vomiting; Normal weight (80%-120% ideal body weight) Exclusion: Significant medical or neurologic illness(concussion, seizure disorder, learning disability, other neurological illness) Current psychotropic medication or medications known to impact cognition Additional Exclusion Criteria for fMRI: Significant Claustrophobia Pregnancy Indwelling metallic object, non-removable metal jewelry, medicinal patch or recent metallic ink tattoo For patients, current psychotropic medications (antidepressants for 2 week (prozac and antipsychotics for 4 weeks) For patients, any other current Axis I diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anorexia nervosa<br>Individuals with anorexia nervosa receiving inpatient treatment | |
| Healthy controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuropsychological functioning |  | pre- and post-treatment |
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®

Study Overview
=================
Brief Summary
-----------------
The primary objective was to determine the efficacy of Human Normal Immunoglobulin (Subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. The secondary objective was to determine the safety of Subgam® given subcutaneously by weekly infusion to patients with primary antibody deficiency.

Official Title
-----------------
A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients.

Conditions
-----------------
Primary Antibody Deficiency

Intervention / Treatment
-----------------
* Biological: Subgam® (Human Normal Immunoglobulin Solution)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The main criteria for inclusion in the study were as follows: A diagnosis of primary antibody deficiency; No lower or upper age limit (any age was eligible); With stable disease and receiving immunoglobulin (IVIG or SCIG) therapy for at least six months prior to starting the study; Written informed consent (patient/parent/guardian). Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subgam®<br> | Biological: Subgam® (Human Normal Immunoglobulin Solution)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of trough levels at each time point where serum IgG was more than equal to 4 g/L |  | Before each infusion in the first 6 months of the study (approximately 30 infusions) |
Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

Study Overview
=================
Brief Summary
-----------------
Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.

Official Title
-----------------
Phase 4 Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms in Patients Using Clozapine. A Randomized, Double-Blind, Placebo Controled Study

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: memantine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Under clozapine with negative symptoms Exclusion Criteria: Pregnancy Lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br>Clozapine plus placebo | Drug: placebo<br>* 1 capsule of placebo twice a day<br>* Other names: Starch;|
| Active Comparator: 2<br>Clozapine plus memantine | Drug: memantine<br>* memantine 10mg twice a day<br>* Other names: Ebixa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score in Brief Psychiatric Raring Scale |  | baseline, 4 weeks, 8 weeks, 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Schizophrenia, negative symptoms, clozapine
Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study

Study Overview
=================
Brief Summary
-----------------
To explore issues patient experience and satisfaction with a sample of patients recently discharged from critical care.

Detailed Description
-----------------
Patients' perceptions of their medical care are of increasing importance to educators, researchers, and clinicians. The emphasis on patient experience and satisfaction is consistent with the trend towards holding health care professionals accountable to their consumers. Our understanding and advancement of patients' experience and satisfaction with care forms a pivotal role in ensuring individuals engage with healthcare services, adhere to therapies, and maintain ongoing relationships with providers. Experiences are best explored using interview techniques such as phenomenological interviewing. In our study we propose to use a hermeneutic phenomenological approach. Phenomenology is a way of qualitatively exploring a person's experience and their personal meanings from those experiences. It is an approach that considers the structure of a person's subjective experience and explores areas that might be hidden. A phenomenological approach looks for patterns that are shared by particular instances or experiences. The evaluation of patient satisfaction and experience is based on valuing patients' subjective perception of an experience. In our study, a phenomenological approach will generate a comprehensive description of a phenomenon or lived experience (i.e. stay in the Critical Care Unit). We will interview a sample of patients to explore experiences and to gain their meanings of their stay in critical care. This will hopefully lead to thinking around ways of improving patient experiences, satisfaction and care.

Official Title
-----------------
Patient Satisfaction in the Critical Care Unit: A Qualitative Phenomenological Study

Conditions
-----------------
Patient Satisfaction in the Critical Care Unit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients who were admitted to the Critical Care Unit at the Royal Marsden Hospital Patients who are not now at the End of Life or palliative. Adults (i.e. patients >18 years of age. Patients staying more than 24 hours. Exclusion Criteria: Very short stay patients (<24 hours)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
C-reactive Protein Levels in Acute Apical Abscess Due to Root Canal Infection

Study Overview
=================
Brief Summary
-----------------
C-reactive protein levels of patients with acute apical abscess are evaluated before and after root canal treatment

Detailed Description
-----------------
In patients with acute apical abscess C-reactive proteins are evaluated before and after root canal treatment. In this intra-canal medications calcium hydroxide and triple antibiotic paste are compared. PAI score of the corresponding tooth is noted .

Official Title
-----------------
Assessment of C-reactive Protein Levels in Acute Apical Abscess Due to Root Canal Infection

Conditions
-----------------
Dentoalveolar Abscess

Intervention / Treatment
-----------------
* Procedure: ROOT CANAL TREATMENT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with acute apical abscess Exclusion Criteria: Teeth with evidence of previous initiated root canal treatment History of myocardial infarction, coronary heart disease Patients allergic to local anesthetic Patients under steroid medication Patients who are immunocompromised

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: calcium hydroxide<br>calcium hydroxide powder is mixed with normal saline and placed as intra-canal medication | Procedure: ROOT CANAL TREATMENT<br>* TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT<br>|
| Experimental: Triple antibiotic paste<br>Triple antibiotic paste (TAP)- combination of metronidazole,ciprofloxacin and minocycline mixed in a ratio of 1:1:1 . TAP paste is combined with propylene glycol and placed as intra canal medication. | Procedure: ROOT CANAL TREATMENT<br>* TWO TYPE OF INTRA CANAL MEDICATION PLACEMENT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post root canal C reactive protein level | Pre-operative serum c-reactive protein level was measured to which the post operative c-reactive protein level after 2 weeks of root canal treatment are compared. The normal serum c-reactive protein level is 0 - 6.00 mg/L. | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain and swelling assessment | pain and swelling reduction after root canal treatment is assessed. . Pain is evaluated using visual analgue scale (VAS) , regarding swellling reduction patient is asked to evaluate subjectively whether the patient profile has returned to normal after the treatment and they were asked how many days it took for the swelling to resolve completely. | 6 months |
Safety Study of Olopatadine Nasal Spray

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.

Official Title
-----------------
Safety Study of Olopatadine Nasal Spray

Conditions
-----------------
Perennial Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: Olopatadine 0.6% nasal spray
* Drug: Placebo Nasal Spray


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with confirmed diagnosis of perennial allergic rhinitis who are 12 years and older Exclusion Criteria: Age 11 years and younger

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Olopatadine 0.6% Nasal Spray<br>2 sprays each nostril twice daily | Drug: Olopatadine 0.6% nasal spray<br>* 2 sprays each nostril twice daily<br>|
| Placebo Comparator: Placebo Nasal Spray<br>2 sprays each nostril twice daily | Drug: Placebo Nasal Spray<br>* 2 sprays each nostril twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire | Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief. | day 30 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Number of Days of Rescue Medication Taken |  | Month 1 through Month 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rhinitis, perennial allergic rhinitis, allergic rhinitis
Hydronephrosis on Ultrasound With CT Finding in Patients With Renal Colic

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the overall sensitivity and specificity of hydronephrosis on point-of-care bedside ultrasound to identify hydronephrosis as compared to hydronephrosis found by CT.

Official Title
-----------------
Correlation of Hydronephrosis on Point of Care Ultrasound With CT Finding in Patients With Expected Renal Colic

Conditions
-----------------
Hydronephrosis, Renal Colic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency Department patients 18 yrs or older with suspected renal colic in whom the clinician intends to obtain a CT scan to diagnose kidney stone. Informed consent will be required prior to enrollment in the study. Exclusion Criteria: Known renal disease (any ESRD, transplant, PCKD), dementia, trauma, language barrier, incarcerated patients, and patients who do not undergo CT.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hydronephrosis bedside ultrasound | To determine the overall sensitivity and specificity of hydronephrosis on point-of-care bedside ultrasound to identify hydronephrosis as compared to hydronephrosis found on by CT. | Sept 2011-Jan 2013 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hydronephrosis bedside ultrasound | To determine test performance characteristics of hydronephrosis on point of care ultrasound with the goal of incorporating POC US into a prospective rule for determining which patients with suspected renal colic require CT evaluation. | Sept 2011-Jan 2013 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hydronephrosis, CT, POC US
The Safety and Efficacy of Adjunct Carvedilol in Children With Moderate Heart Failure

Study Overview
=================
Brief Summary
-----------------
We would like to see if using Carvedilol in adjunct with Ace inhibitors will increase ejection fraction of the heart under echo. All interpretation of data will be sent to Boston Children's Hospital to be reviewed, which is the primary research center in this study. There are 5 hospitals participating in this study. The population targeted are children with moderate heart failure and must be on Ace inhibitors at the time of enrollment. Our outcome after placing them on Carvedilol is to change their ejection fraction on echo. The patients will be seen every 1-2 weeks, while we will titrate their medication to a maintenance dose. Secondary outcome is to increase quality of life, exercise tolerance and decrease their symptom scores as noted on their questionnaires.

Conditions
-----------------
Heart Diseases

Intervention / Treatment
-----------------
* Drug: Carvedilol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Etiology of heart failure in Group 1 or Group 2 Moderate heart failure as evidenced by ventricular shortening fraction <= standard deviations below the mean, or ejection fraction <= 40% d) documented shortening fraction or ejection fraction that meet criteria for greater than 3 months Standard medical therapy include ACE inhibitors plus or minus diuretics plus or minus digoxin; all efforts will made to maximize therapy prior to entry. Medication doses must be stable for 3 months prior to entry Willingness to comply with followup testing

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Carvedilol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
moderate heart failure
Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure motor fluctuations and dyskinesias in patients with Parkinson's disease using movement sensors (accelerometers and gyroscopes) to determine if this is a feasible measure to use in addition to self report, and eventually the goal will be to replace self report with a more reliable measure such as movement sensors.

Detailed Description
-----------------
Patients with Parkinson disease and motor fluctuations will wear movement sensors during their regular clinic visit with the principal investigator. The visit will be videotaped and medication status (ON without dyskinesia, ON with dyskinesia, or OFF) will be independently rated from review of the video.

Official Title
-----------------
Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who will be included in the study have probable or definite idiopathic PD (CAPSIT criteria (23)), Hoehn & Yahr stage 2-4; One or more of the following PD-associated motor impairments experienced in the week prior to enrollment (based on history and/or examination): motor fluctuations (end of dose wearing off with hypokinesia and/or levodopa-induced choreiform dyskinesias), tremor, freezing of gait, or frequent falls (≥ 1 per week). Exclusion Criteria: Neurological disorders (other than PD) or orthopedic deficits that, in the investigator's judgement, contribute substantially to impaired movement (e.g. stroke with motor sequelae; Essential tremor; Severe osteoarthritis); Cognitive impairment sufficiently severe to interfere with informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1-3Hz gyroscope signal power |  | 30 second windows spanning the observation period |
Intrauterine Embryo Development With ANECOVA Device

Study Overview
=================
Brief Summary
-----------------
We aim to compare the morphological and chromosomal features of human embryos cultured In Vitro versus those developed in a new In Vivo culture system with encapsulation in utero as well as implantation and pregnancy rate.

Official Title
-----------------
Multi-Center Evaluation Program NCVD1H Intrauterine Embryo'S Development Assisted by ANECOVA ACVd1 Device

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women age below 37 Hormonal serum levels within normal ranges (FSH, LH, E2, PRL, P4, T4, TSH) Negative serologic screening for HIV, Hep B and C No uterine or ovarian alterations found by ultrasound Normal BMI (19 - 29 kg/m2). Exclusion Criteria: At least 8 stage MII oocytes are not retrieved Endometriosis or PCO Severe male factor in the partner

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Embryo morphological and chromosomal features, Implantation and pregnancy rate